Search
ADMA Biologics Inc
ADMAAdd to Watchlist
8.460USD
-0.210-2.42%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.96BMarket Cap
12.16P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of ADMA Biologics Inc is 7.50, ranking 103 out of 155 in the Pharmaceuticals industry. The average price target is 30.00, with a high of 32.00 and a low of 17.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
17.000
Target Price
+100.95%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
ADMA Biologics Inc
ADMA
5
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is ADMA Biologics Inc's expected revenue for the next quarter?
ADMA Biologics Inc's expected revenue is 131.66M.
What is ADMA Biologics Inc's price target?
Analysts forecast that ADMA Biologics Inc's price target is USD 30.00, with the highest forecast at USD 32.00 and the lowest forecast at USD 17.00.
How have ADMA Biologics IncADMA's recent earnings per share performed?
The market expectation was USD 0.19, while ADMA Biologics IncADMA's earnings per share (EPS) for the previous quarter was USD 0.21. EPS for the next quarter is expected at USD 0.17.
What is the analyst rating for ADMA Biologics Inc?
Based on the ratings of ADMA Biologics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.